Released May 17, 2021, after the close
10-Q filed May 17, 2021, 47 days after period end · 0001140361-21-017648
Q1 2021 · 10-Q
Revenue—
Net Income-$18.52M-$18.52M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.67-$0.67 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$8,921,000N/M
Operating Cash Flow-$3,430,000N/M
Free Cash Flowderived-$3,430,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | — | $2.39M | $4.83M | $5.76M |
| Net Income | -$18.52M | -$1.02M | -$313.00K | -$409.00K |
| EPS Diluted | -$0.67 | -$0.06 | -$0.11 | -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR